Candesartan cilexetil

Key facts

Invented name
Atacand and associated name
Active substance
Candesartan cilexetil
Therapeutic area
Cardiovascular diseases
Decision number
P/21/2009
PIP number
Candesartan cilexetil
Pharmaceutical form(s)
  • Tablets
  • Suspension for oral use
Condition(s) / indication(s)
  • Diabetic retinopathy
  • Heart Failure
  • Essential hypertension
Route(s) of administration
Oral use
Contact for public enquiries
AstraZeneca AB

E-mail: paediatrics@astrazeneca.com
Tel. +44 20 7304 5345

Decision type
RP: decision refers to a refusal on a proposed Paediatric Investigation Plan

Decision

How useful was this page?

Add your rating